AMT-101 (oral)

Phase 2

4D Molecular Therapeutics, Inc. (FDMT)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Ulcerative Colitis

Drug Information

Target Indication

Ulcerative Colitis

Clinical Trial

NCT05372939

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

FDMT

4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

11C-choline InjectionPhase 3

Metastatic Prostate Cancer

mycophenolate mofetilPhase 3

Familial Lipoprotein Lipase Deficiency

4D-150 IVT (3E10 vg/eye)Phase 3

Neovascular Age-Related Macular Degeneration (nAMD)

EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3

Macular Neovascularization Secondary to Age-Related Macular Degeneration

4D-150 IVTPhase 2

Diabetic Macular Edema

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts